Detailed in vitro analyses of the impact of multimodal cancer therapy with hyperthermia and radiotherapy on the immune phenotype of human glioblastoma cells

References

• Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):796–300.
   Web of Science ®Google Scholar
• Davis ME. Glioblastoma: Overview of disease and treatment. Clin J Oncol Nurs. 2016;20(5 Suppl):S2–S8.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. 043330.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with Tumor-Treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535–2543.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: Primary brain and Central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17(suppl 4):iv1–62.
   PubMed Web of Science ®Google Scholar
• Kocher M, Frommolt P, Borberg SK, et al. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol. 2008;184(11):572–579.
   PubMed Web of Science ®Google Scholar
• Lawrence YR, Li XA, el Naqa I, et al. Radiation dose-volume effects in the brain. Int. J. Radiat. Oncol. Biol. Phys. 2010;76(3):S20–S27.
   PubMed Web of Science ®Google Scholar
• Straube C, Combs SE. [Combining radiation plus temozolomide in glioblastoma patients older than 65 years of age]. Strahlenther Onkol. 2017;193(6):510–512.
   PubMed Web of Science ®Google Scholar
• Fietkau R. [Concurrent radiochemotherapy for the treatment of solid tumors]. Strahlenther Onkol. 2012;188(Suppl 3):263–271.
   PubMed Web of Science ®Google Scholar
• Putz F, Putz T, Goerig N, et al. Improved survival for elderly married glioblastoma patients : Better treatment delivery, less toxicity, and fewer disease complications. Strahlenther Onkol. 2016;192(11):797–805.
   PubMed Web of Science ®Google Scholar
• Nabors L, Horbinski C, Robins I. NCC guidelines in oncology (NCCN guidelines®), national comprehensive cancer network. 2019.
   Google Scholar
• Ghouzlani A, Kandoussi S, Tall M, et al. Immune checkpoint inhibitors in human glioma microenvironment. Front Immunol. 2021;12:679425.
   PubMed Web of Science ®Google Scholar
• Lee EQ. Immune checkpoint inhibitors in GBM. J Neurooncol. 2021;155(1):1–11.
   PubMed Web of Science ®Google Scholar
• Han M-Z, Wang S, Zhao W-B, et al. Immune checkpoint molecule herpes virus entry mediator is overexpressed and associated with poor prognosis in human glioblastoma. EBioMedicine. 2019;43:159–170.
   PubMed Web of Science ®Google Scholar
• Agarwal P, Beale OM, Zhang X, et al. Machine learning identification of immunotherapy targets in Low-Grade glioma using RNA sequencing expression data. World Neurosurg. 2022. DOI:10.1016/j.wneu.2022.03.123
   Web of Science ®Google Scholar
• Jahan N, Talat H, Alonso A, et al. Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma. Oncoimmunology. 2019;8(5):e1577108.
   PubMed Web of Science ®Google Scholar
• Seyfrid M, Maich WT, Shaikh VM, et al. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment. J Immunother Cancer. 2022; 10(1):e003289.
   PubMed Web of Science ®Google Scholar
• Nduom EK, Weller M, Heimberger AB. Immunosuppressive mechanisms in glioblastoma. Neuro Oncol. 2015;17(Suppl 7):vii9–14.
   PubMed Web of Science ®Google Scholar
• Busch W. Über den einfluss welche heftigere erysipeln zuweilig auf organisierte neubildungen ausüben. Verhandlungen Des Naturhistorischen Vereines Der Preussischen Rheinlande Und Westphalens. 1866;23:28–30.
   Google Scholar
• Rosenblum AS. Relation of febrile diseases to the psychoses: translation from trudi vrach and odessk G. Boln, 1876-77, vol. 2, part B, by zakon S. J. with comments by neymann C. A. Arch Dermatol Res. 1943;48:52–58.
   Google Scholar
• Toraya-Brown S, Fiering S. Local tumour hyperthermia as immunotherapy for metastatic cancer. Int J Hyperthermia. 2014;30(8):531–539.
   PubMed Web of Science ®Google Scholar
• van der Zee J. Heating the patient: a promising approach? Ann Oncol. 2002;13(8):1173–1184.
   PubMed Web of Science ®Google Scholar
• Kalamida D, Karagounis IV, Mitrakas A, et al. Fever-range hyperthermia vs. hypothermia effect on cancer cell viability, proliferation and HSP90 expression. PLoS ONE. 2015;10(1):e0116021.
   PubMed Web of Science ®Google Scholar
• Lee TW, Murad GJA, Hoh BL, Rahman M. fighting fire with fire: the revival of thermotherapy for gliomas. Anticancer Res. 2014;34:565–574.
   PubMed Web of Science ®Google Scholar
• Kampinga HH. Cell biological effects of hyperthermia alone or combined with radiation or drugs: a short introduction to newcomers in the field. Int J Hyperthermia. 2006;22(3):191–196.
   PubMed Web of Science ®Google Scholar
• Hader M, Streit S, Rosin A, et al. In vitro examinations of cell death induction and the immune phenotype of cancer cells following Radiative-Based hyperthermia with 915 MHz in combination with radiotherapy. Cells. 2021;10(6):1436.
   PubMed Web of Science ®Google Scholar
• Hader M, Savcigil DP, Rosin A, et al. Differences of the immune phenotype of breast cancer cells after ex vivo hyperthermia by Warm-Water or microwave radiation in a Closed-Loop system alone or in combination with radiotherapy. Cancers. 2020;12(5):1082.
   PubMed Web of Science ®Google Scholar
• Franckena M, Stalpers LJA, Koper PCM, et al. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the dutch deep hyperthermia trial. Int J Radiat Oncol Biol Phys. 2008;70(4):1176–1182.
   PubMed Web of Science ®Google Scholar
• Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107(6):912–918.
   PubMed Web of Science ®Google Scholar
• Hulshof M, Raaymakers BW, Lagendijk JJW, et al. A feasibility study of interstitial hyperthermia plus external beam radiotherapy in glioblastoma multiforme using the multi ELectrode current source (MECS) system. Int J Hyperthermia. 2004;20(5):451–463.
   PubMed Web of Science ®Google Scholar
• Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103(2):317–324.
   PubMed Web of Science ®Google Scholar
• Mahmoudi K, Bouras A, Bozec D, et al. Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy's history, efficacy and application in humans. Int J Hyperthermia. 2018;34(8):1316–1328.
   PubMed Web of Science ®Google Scholar
• Sneed PK, Stauffer PR, McDermott MW, et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme. Inter J Rad Oncol Biol Phys. 1998;40(2):287–295.
   PubMed Web of Science ®Google Scholar
• Oberacker E, Kuehne A, Oezerdem C, et al. Radiofrequency applicator concepts for thermal magnetic resonance of brain tumors at 297 MHz (7.0 Tesla)). Int J Hyperthermia. 2020;37(1):549–563.
   PubMed Web of Science ®Google Scholar
• Alphandéry E, Grand-Dewyse P, Lefèvre R, et al. Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. Expert Rev Anticancer Ther. 2015;15(10):1233–1255.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306–2316.
   PubMed Web of Science ®Google Scholar
• Henry CM, Hollville E, Martin SJ. Measuring apoptosis by microscopy and flow cytometry. Methods. 2013;61(2):90–97.
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148.
   PubMed Web of Science ®Google Scholar
• D'Incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015;112(1):95–102.
   PubMed Web of Science ®Google Scholar
• Deloch L, Derer A, Hartmann J, et al. Modern radiotherapy concepts and the impact of radiation on immune activation. Front Oncol. 2016;6:141.
   PubMed Web of Science ®Google Scholar
• Rückert M, Deloch L, Fietkau R, et al. Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies. Strahlenther Onkol. 2018;194(6):509–519.
   PubMed Web of Science ®Google Scholar
• Hader M, Frey B, Fietkau R, et al. Immune biological rationales for the design of combined radio- and immunotherapies. Cancer Immunol Immunother. 2020;69(2):293–306.
   PubMed Web of Science ®Google Scholar
• van Leeuwen CM, Crezee J, Oei AL, et al. The effect of time interval between radiotherapy and hyperthermia on planned equivalent radiation dose. Int J Hyperthermia. 2018;34(7):901–909.
   PubMed Web of Science ®Google Scholar
• Mei X, Cate R t, van Leeuwen CM, et al. Radiosensitization by hyperthermia: the effects of temperature, sequence, and time interval in cervical cell lines. Cancers. 2020;12(3):582.
   PubMed Web of Science ®Google Scholar
• Barnes JA, Dix DJ, Collins BW, et al. Expression of inducible Hsp70 enhances the proliferation of MCF-7 breast cancer cells and protects against the cytotoxic effects of hyperthermia. Cell Stress Chaper. 2001;6(4):316–325. > 2.0.co;2.
   PubMed Web of Science ®Google Scholar
• Multhoff G, Pockley AG, Streffer C, et al. Dual role of heat shock proteins (HSPs) in anti-tumor immunity. Curr Mol Med. 2012;12(9):1174–1182.
   PubMed Web of Science ®Google Scholar
• Li H, Lei B, Xiang W, et al. Differences in protein expression between the U251 and U87 cell lines. Turk Neurosurg. 2017;27(6):894–903.
   PubMed Web of Science ®Google Scholar
• Euw E v, Barrio MM, Furman D, et al. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. J Transl Med. 2007;5:19.
   PubMed Web of Science ®Google Scholar
• Frey B, Rückert M, Weber J, et al. Hypofractionated irradiation has immune stimulatory potential and induces a timely restricted infiltration of immune cells in Colon cancer tumors. Front Immunol. 2017;8:231.
   PubMed Web of Science ®Google Scholar
• Linder M, Pogge von Strandmann E. The role of extracellular HSP70 in the function of Tumor-Associated immune cells. Cancers. 2021;13(18):4721.
   PubMed Web of Science ®Google Scholar
• Andersen MH. The balance players of the adaptive immune system. Cancer Res. 2018;78(6):1379–1382.
   PubMed Web of Science ®Google Scholar
• Derer A, Spiljar M, Bäumler M, et al. Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells. Front Immunol. 2016;7:610.
   PubMed Web of Science ®Google Scholar
• Buchwald ZS, Wynne J, Nasti TH, et al. Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation. Front Oncol. 2018;8:612.
   PubMed Web of Science ®Google Scholar
• Lim YJ, Koh J, Kim S, et al. Chemoradiation-Induced alteration of programmed Death-Ligand 1 and CD8+ Tumor-Infiltrating lymphocytes identified patients with poor prognosis in rectal cancer: a matched comparison analysis. Int J Radiat Oncol Biol Phys. 2017;99(5):1216–1224.
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458–5468.
   PubMed Web of Science ®Google Scholar
• Hecht M, Büttner-Herold M, Erlenbach-Wünsch K, et al. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer. 2016;65:52–60.
   PubMed Web of Science ®Google Scholar
• Frey B, Weiss E-M, Rubner Y, et al. Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperthermia. 2012;28(6):528–542.
   PubMed Web of Science ®Google Scholar
• Wimmer S, Deloch L, Hader M, et al. Hypofractionated radiotherapy upregulates several immune checkpoint molecules in head and neck squamous cell carcinoma cells independently of the HPV status while ICOS-L is upregulated only on HPV-Positive cells. Int J Mol Sci. 2021;22(17):9114.
   PubMed Web of Science ®Google Scholar
• Hall PE, Schmid P. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials. Expert Opin Emerg Drugs. 2021;26(2):131–147.
   PubMed Web of Science ®Google Scholar
• Datta NR, Ordóñez SG, Gaipl US, et al. Local hyperthermia combined with radiotherapy and-/or chemotherapy: recent advances and promises for the future. Cancer Treat Rev. 2015;41(9):742–753.
   PubMed Web of Science ®Google Scholar
• Williamson CW, Sherer MV, Zamarin D, et al. Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety. Cancer. 2021;127(10):1553–1567.
   PubMed Web of Science ®Google Scholar
• Zhou J-G, Donaubauer A-J, Frey B, et al. Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors 2020.
   Google Scholar
• Huang Y, Bert C, Sommer P, et al. Deep learning for brain metastasis detection and segmentation in longitudinal MRI data. 2021. http://arxiv.org/pdf/2112.11833v2.
   Google Scholar
• Scheidegger S, Mingo Barba S, Gaipl US. Theoretical evaluation of the impact of hyperthermia in combination with radiation therapy in an artificial Immune-Tumor-Ecosystem. Cancers. 2021;13(22):5764.
   PubMed Web of Science ®Google Scholar
• Zhou J-G, Donaubauer A-J, Frey B, et al. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors. J Immunother Cancer. 2021;9(2):e001845.
   PubMed Web of Science ®Google Scholar
• Hecht M, Eckstein M, Rutzner S, et al. Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. J Immunother Cancer. 2022;10(1):e003747.
   PubMed Web of Science ®Google Scholar
• Platten M. Vergleichbare effekte auf das gesamtüberleben. InFo Neurologie. 2021;23(3):18–18.
   Google Scholar
• Persico P, Lorenzi E, Dipasquale A, et al. Checkpoint inhibitors as High-Grade gliomas treatment: State of the art and future perspectives. J Clin Med. 2021;10(7):1367.
   PubMed Web of Science ®Google Scholar
• Weller M, Lim M, Idbaih A, et al. CTIM-25. A randomized phase 3 study of nivolumab or placebo combined with radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma with methylated mgmt promotor: checkmate 548. Neuro Oncol. 2021;23:55–56.
   Google Scholar